Translational Session
Changing Landscape of Diabetic Kidney Disease Treatment, Including the Robert W. Schrier, MD, Endowed Lectureship
November 02, 2023 | 10:30 AM - 12:30 PM
Location: Ballroom A, Pennsylvania Convention Center
Session Description
The therapeutic landscape of diabetic kidney disease is rapidly evolving. This session opens with a comprehensive overview of the mechanisms of action of novel therapies in the field, as well as unmet needs in the field. Subsequently, updates on recent advances in this arena are provided, with a particular focus on SGLT2 inhibition and GLP1 receptor agonists.
ASN gratefully acknowledges Otsuka America Pharmaceutical, Novartis, Astellas Pharma US, and several individuals for support of the Robert W. Schrier, MD, Endowed Lectureship.
Learning Objective(s)
- Describe the mechanisms of action of novel therapies in diabetic kidney disease
- Summarize the unmet needs in the therapeutic landscape of diabetic kidney disease
- Discuss updates on GLP1 receptor agonists' use
- Discuss updates on GLP1 receptor agonists' mechanisms and their use
Learning Pathway(s)
- Diabetic Kidney Disease
- CKD Non-Dialysis
Moderators
Presentations
- Novel Therapies: On the Mechanisms of Action: The Robert W. Schrier, MD, Endowed Lectureship
10:30 AM - 11:00 AM
- Unmet Treatment Needs for Diabetic Kidney Disease
11:00 AM - 11:30 AM
- Are SGLT2 Inhibitors New Again?
11:30 AM - 12:00 PM
- GLP1 Receptor Agonists: On the Mechanism
12:00 PM - 12:30 PM